CRISPR-Cas9 gene-editing paper (Doudna and Charpentier)
Draft: not yet verifiedScience, invention & breakthrough technology
Why it matters
Cheap, precise gene editing; Nobel Prize 2020
- Era
- GFC & euro crisis (2007–12)
- Track
- Technology & science
- Asset classes
- Equities
- Wikipedia
- CRISPR gene editing (article on this event)
- Date check
- no date in Wikidata
Open in the interactive timeline, with its macro chartsSuggest a correction
Sources
References cited in the Wikipedia article, official and academic ones first.
- A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenit — Nature Medicine (2018) (Academic)
- CRISPR: gene editing is just the beginning — Nature (2016) (Academic)
- CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis — The New England Journal of Medicine (2021) (Academic)
- UC Berkeley Will Auction NFTs for 2 Nobel Prize Patents (2021) (Academic)
- RNA editing with CRISPR-Cas13 — Science (2017) (Academic)
Connected events
Events whose Wikipedia articles link to this one. Links show relatedness, not cause.
- 16 November 2023 First CRISPR therapy approved (Casgevy, UK; US FDA on Dec 8) · Global (origin GBR)
Gene editing moves from lab to clinic
← Tesla Model S deliveries begin: EVs go mainstream at the top endAlexNet wins ImageNet: deep learning on Nvidia GPUs →
Previous and next events on the Technology & science track.
Cite this event
Wang, Y. (2026). CRISPR-Cas9 gene-editing paper (Doudna and Charpentier) (28 June 2012). In Macro-financial history, 1900–2026, event E0443. https://macrofinancialhistory.com/event/e0443/
@misc{mefh_e0443,
author = {Wang, Yuhui},
title = {CRISPR-Cas9 gene-editing paper (Doudna and Charpentier)},
howpublished = {Macro-financial history, 1900–2026, event E0443},
year = {2026},
url = {https://macrofinancialhistory.com/event/e0443/}
}